📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. (2019)

First Author: Weston M

Attributed to: Gene therapy for refractory epilepsy funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/sciadv.aaw1567

PubMed Identifier: 31001591

Publication URI: http://europepmc.org/abstract/MED/31001591

Type: Journal Article/Review

Volume: 5

Parent Publication: Science advances

Issue: 4

ISSN: 2375-2548